---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-166987"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2026-04-21T23:59:59+00:00"
generated_at: "2026-05-15T05:08:50.320524+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aligos licenses pevifoscorvir sodium to Amoytop for China/Taiwan/HK/Macau; upfront $25M, milestones up to $420M

## Summary
- Exclusive license to develop and commercialize pevifoscorvir sodium for HBV and HBV/HDV in mainland China, Taiwan, Hong Kong, and Macau.
- Upfront cash payment of $25 million from Amoytop; eligible for up to $420 million in development, regulatory, and commercial milestones.
- Tiered high single-digit royalties on net sales in the Territory.
- Amoytop responsible for all development, regulatory, manufacturing, and commercialization costs in the Territory.
- Effectiveness conditional on Amoytop shareholder approval within 45 days of signing.

## SEC filing metadata
- accession: 0001193125-26-166987
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2026-04-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000119312526166987/0001193125-26-166987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000119312526166987/d50981d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-166987
- JSON: https://secwatch.observer/filing/0001193125-26-166987.json
- Plain text: https://secwatch.observer/filing/0001193125-26-166987.txt

## Source-grounded claims
- claim_id: 77dc774fbcde45de3769f9272c22c5a7a13ca9c6
  claim: Aligos Therapeutics, Inc. entered into License Agreement with Xiamen Amoytop Biotech Co., Ltd. valued at $25 million (effective 2026-04-16).
  evidence_excerpt: On April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), pursuant to which the Company grants to Amoytop an exclusive, non-transferable, royalty-bearing license, under certain Company-controlled intellectual property, to manufacture, develop and commercialize the Company’s investigational compound pevifoscorvir sodium in its current dosage form, formulation, and mode of administration (the “Licensed Product”) in the field of the treatment, prevention or palliation of Hepatitis B virus infection in humans, or Hepatitis B virus and Hepatitis D virus co-infection in humans (the “Field”), in the territory of mainland China, Taiwan, and the Special Administrative Regions of Hong Kong and Macau (the “Territory”). Amoytop has the right to have the Licensed Product made in the Territory by manufacturers meeting certain criteria, and to sublicense its rights, subject to certain rest
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799448/000119312526166987/0001193125-26-166987-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.